Catalyst Pharmaceuticals Announces Third Quarter 2020 Financial Results and Provides Business Update
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/24/2026
- Wall St set to open higher as tech rebounds, Micron earnings eyed
- Brent extends losses on expectations of smoother crude flows via Hormuz
- All eyes on Micron earnings tonight as sell-off raises stakes for AI memory trade
- Alphabet added to Dow Jones Industrial Average, Verizon dropped
- Stay long AI-capex winners into the peak, Stifel says despite bubble fears
- Needham Starts NeoVolta (NEOV) at Buy
- Wall Street ends lower on semiconductor selloff as AI spending concerns mount
- NextEra to discuss paying about $76 per share for Dominion, Bloomberg News reports
- Campbell Soup (CPB) Declares $0.39 Quarterly Dividend; 7.7% Yield
- KKR launches Helix with over $10 billion to build AI infrastructure
Catalyst Pharmaceuticals (CPRX) Tops Q3 EPS by 32c, Revenues Miss
November 9, 2020 5:24 PM ESTCatalyst Pharmaceuticals (NASDAQ: CPRX) reported Q3 EPS of $0.42, $0.32 better than the analyst estimate of $0.10. Revenue for the quarter came in at $29.2 million versus the consensus estimate of $31.49 million.
Excluding expenses related to stock-based compensation of $1.5 million, non-GAAP1 net income for the third quarter of 2020 was $44.8 million, or $0.43 per basic and $0.42 per diluted share.This compares to non-GAAP1 net income of $14.4 million, or $0.14 per basic share and $0.13... More